Aurobindo Pharma, a manufacturer of generic pharmaceuticals and active pharmaceutical ingredients headquartered at Hyderabad, received final approval from the US Food and Drug Administration (USFDA) for cefazolin for Injection USP 500 mg.vial and 1 gram/vial.
This is a sterile cephalosporin product under the anti-nfective segment and generic equivalent to Abraxis Pharmaceutical Products' Reference Listed drug Cefazolin for injections USP 500 mg.vial and 1 gram /vial. This is the third product approval by the USFDA for the sterile injectable formulation line of Unit VI-B, situated in Hyderabad. Aurobindo now has 74 abbreviated new drug applications (ANDAs) approved by the USFDA, according to a press release.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app